Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03367403 · ClinicalTrials.gov registry record · Phase 2
A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)
A Phase 2 study of Alzheimer Disease, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 272
- Enrollment target
- 20
- Study locations
NCT03367403 is a Phase 2 study of Alzheimer Disease that has completed, run by Eli Lilly and Company. The registered enrollment target is 272 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT03367403, a Phase 2 study of Alzheimer Disease, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 272 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability and efficacy of LY3002813 in early symptomatic Alzheimer's disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Donanemab
- DRUG LY3202626
Study Locations (20)
Florida
- JEM Research Institute - Atlantis
- Bradenton Research Center - Bradenton
- Brain Matters Research - Delray Beach
- Infinity Clinical Research, LLC - Hollywood
- Jacksonville Center for Clinical Research - Jacksonville
- Merritt Island Medical Research LLC - Merritt Island
- Pharmax Research Clinic - Miami
- Miami Jewish Health Systems - Miami
- Suncoast Clinical Research - New Port Richey
California
- Neurology Center of North Orange County - Fullerton
- Irvine Clinical Research Center - Irvine
- Institute for Memory Impairment & Neurological Disorders - Irvine
- Pharmacology Research Institute - Newport Beach
- Pacific Research Network Inc - San Diego
- Sharp Mesa Vista Hospital - San Diego
- Syrentis Clinical Research - Santa Ana
Arizona
- Banner Alzheimer's Institute - Phoenix
- Banner Sun Health Research Institute - Sun City
Connecticut
- Associated Neurologists, PC - Danbury - Danbury
- KI Health Partners, LLC d/b/a NE Inst. for Clin. Res. - Stamford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 272 participants |
| Start Date | 2017-12-18 |
| Est. Completion | 2021-09-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03367403
The ClinicalTrials.gov registry entry for NCT03367403 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 272 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (90% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03367403 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT03367403 about?
NCT03367403 is a clinical study titled "A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)". The purpose of this study is to evaluate the safety, tolerability and efficacy of LY3002813 in early symptomatic Alzheimer's disease.
What is the current status of trial NCT03367403?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 272 participants. The study started on 2017-12-18. Estimated completion is 2021-09-21.
What conditions does trial NCT03367403 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT03367403?
The interventions under investigation include: Placebo (DRUG), Donanemab (DRUG), LY3202626 (DRUG).
Who is sponsoring clinical trial NCT03367403?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03367403 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
RECRUITING · Phase 2
-
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
RECRUITING · Phase 2
-
Sleep Trial to Prevent Alzheimer's Disease
RECRUITING · Phase 2
-
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
RECRUITING · Phase 2
-
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.